PROX1 and central nervous system cancer: Since Grade II gliomas exhibit a highly variable course and can transform into a more malignant phenotype at any time, the same group of researchers conducted another study in order to evaluate PROX1 as a predictive and prognostic marker in Grade-II gliomas [19].